ReviewFrontiers in psychiatry2018
Biological Mechanisms of Cancer-Induced Depression.
Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Depression increases cancer mortality by 23-83%: a meta-analysis of 65 studies across five major cancer types.GeroScience · 2026Pooled it
- Using eHealth to Support Quality of Life and Well-Being in Patients With Lung Cancer: Systematic Review.JMIR cancer · 2025Pooled it
- Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.Cancer reports (Hoboken, N.J.) · 2026Review
- Depression and long-term mortality among 5-year breast cancer survivors in Korea: a retrospective population-based cohort study.Scientific reports · 2026Article
- Brain metabolic vulnerability in 18-F FDG PET/CT predict future depression risk in young cancer survivors.Translational psychiatry · 2025Observational
- Mental Comorbidity and Psychosocial Care in Patients with Cancer.Deutsches Arzteblatt international · 2025Article
- New highlights in cancer and depression multimorbidity: a scoping systematic review.Frontiers in oncology · 2025Review
- The Effectiveness of Mindfulness-Based Cognitive Therapy to Improve Anxiety Symptoms and Quality of Life in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.Cancers · 2024Review
- [Rational treatment of depressive syndromes in brain tumor patients].Der Nervenarzt · 2024Review
- Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival.Current oncology reports · 2024Review
- Research progress on ferroptosis in gliomas (Review).Oncology letters · 2024Review
- Understanding the Role of Polyunsaturated Fatty Acids in the Development and Prevention of Cancer.Cancer treatment and research · 2024Review
- Elevated neopterin and decreased IL-4, BDNF levels and depression in lymphoma patients receiving R-CHOP chemotherapy.Frontiers in neurology · 2024Article
- The Antidepressant Activity of a Taurine-Containing Derivative of 4-Phenylpyrrolidone-2 in a Model of Chronic Unpredictable Mild Stress.International journal of molecular sciences · 2023Article
- Depressed Mood as a Significant Risk Factor for Gynecological Cancer Aggravation.International journal of environmental research and public health · 2023Article
- Effects of music therapy on anxiety in patients with cancer: study protocol of a randomised controlled trial.BMJ open · 2023Article
- α7 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect.Journal of neuroinflammation · 2023Review
- Article
- A broken circadian clock: The emerging neuro-immune link connecting depression to cancer.Brain, behavior, & immunity - health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer are more likely to develop depression than the general population, which negatively impacts their quality of life and prognosis. In order to identify effective antidepressants catered toward cancer patients, the biology of depression in the context of cancer must be well-understood. Many theories have emerged postulating the mechanisms underlying the development of depressive disorder. Here, we review the role inflammation, a hyperactive hypothalamic-pituitary-adrenal (HPA) axis, and glutamate excitotoxicity may play in cancer-induced depression. Hopefully, novel therapeutics targeting these dysregulated pathways may be potent in ameliorating depressive symptoms in the cancer population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.